PE20170189A1 - Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 - Google Patents
Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1Info
- Publication number
- PE20170189A1 PE20170189A1 PE2016002391A PE2016002391A PE20170189A1 PE 20170189 A1 PE20170189 A1 PE 20170189A1 PE 2016002391 A PE2016002391 A PE 2016002391A PE 2016002391 A PE2016002391 A PE 2016002391A PE 20170189 A1 PE20170189 A1 PE 20170189A1
- Authority
- PE
- Peru
- Prior art keywords
- pyrazolo
- malt1
- inhibitors
- optionally substituted
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE PIRAZOLO PIRIMIDINA DE FORMULA (I) DONDE R1 ES HALOGENO, CIANO O ALQUILO C1-C3 OPCIONALMENTE SUSTITUIDO CON HALOGENO; R2 ES ALQUILO C1-C6, CICLOALQUILO C3-C6, FENILO, ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS; R ES FENILO OPCIONALMENTE SUSTITUIDO. SON COMPUESTOS PREFERIDOS: (S)-1-(6-(2H-1,2,3-TRIAZOL-2-IL)-5-(TRIFLUOROMETIL)PIRIDIN-3-IL)-3-(2-CLORO-7-(1-METOXIETIL)PIRAZOLO[1,5-a]PIRIMIDIN-6-IL)UREA; (S)-1-(2-CLORO-7-(1-METOXIETIL)PIRAZOLO[1,5-a]PIRIMIDIN-6-IL)-3-(2-(TRIFLUOROMETIL)PIRIDIN-4-IL)-UREA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA 1 DE TRASLOCACION DE LINFOMA ASOCIADO A LA MUCOSA DE TEJIDO LINFOIDE (MALT1) SIENDO UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ESCLEROSIS MULTIPLE, LUPUS ERITEMATOSO SISTEMICO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14170408 | 2014-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170189A1 true PE20170189A1 (es) | 2017-03-15 |
Family
ID=50828759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016002391A PE20170189A1 (es) | 2014-05-28 | 2015-05-27 | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US9815842B2 (es) |
| EP (1) | EP3149001B1 (es) |
| JP (1) | JP6545197B2 (es) |
| KR (1) | KR20170007311A (es) |
| CN (1) | CN106170489B (es) |
| AP (1) | AP2016009487A0 (es) |
| AR (1) | AR100645A1 (es) |
| AU (1) | AU2015265478B2 (es) |
| BR (1) | BR112016024545A2 (es) |
| CA (1) | CA2945077A1 (es) |
| CL (1) | CL2016002942A1 (es) |
| CR (1) | CR20160548A (es) |
| CU (1) | CU24393B1 (es) |
| CY (1) | CY1121946T1 (es) |
| DK (1) | DK3149001T3 (es) |
| EA (1) | EA032050B1 (es) |
| ES (1) | ES2738695T3 (es) |
| GT (1) | GT201600249A (es) |
| HR (1) | HRP20191261T1 (es) |
| HU (1) | HUE044351T2 (es) |
| IL (1) | IL247949A0 (es) |
| LT (1) | LT3149001T (es) |
| MX (1) | MX373846B (es) |
| MY (1) | MY182487A (es) |
| PE (1) | PE20170189A1 (es) |
| PH (1) | PH12016501862B1 (es) |
| PL (1) | PL3149001T3 (es) |
| PT (1) | PT3149001T (es) |
| RS (1) | RS59039B1 (es) |
| SG (1) | SG11201607895PA (es) |
| SI (1) | SI3149001T1 (es) |
| SV (1) | SV2016005328A (es) |
| TR (1) | TR201910730T4 (es) |
| TW (1) | TWI709561B (es) |
| UY (1) | UY36143A (es) |
| WO (1) | WO2015181747A1 (es) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX387728B (es) | 2010-06-03 | 2025-03-18 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| BR112015001690A2 (pt) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) |
| EP3341007B1 (en) | 2015-08-28 | 2020-12-23 | Cornell University | Malt1 inhibitors and uses thereof |
| US20200289514A1 (en) * | 2015-11-13 | 2020-09-17 | Novartis Ag | Novel Pyrazolo Pyrimidine Derivatives |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| CN107296807B (zh) * | 2016-04-15 | 2020-03-20 | 中国科学院上海生命科学研究院 | Malt1靶向抑制物在制备malt1依赖性肿瘤治疗药物中的应用 |
| WO2018019755A1 (en) | 2016-07-26 | 2018-02-01 | Basf Se | Herbicidal pyridine compounds |
| WO2018019721A1 (en) | 2016-07-26 | 2018-02-01 | Basf Se | Herbicidal pyridine compounds |
| BR112019001824A2 (pt) | 2016-07-29 | 2019-05-07 | Lupin Limited | compostos de tiazol-piridina substituídos como inibidores de malt1 |
| WO2018021520A1 (ja) | 2016-07-29 | 2018-02-01 | 東レ株式会社 | グアニジン誘導体及びその医薬用途 |
| PE20190656A1 (es) | 2016-07-29 | 2019-05-08 | Lupin Ltd | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 |
| US10689366B2 (en) | 2016-11-01 | 2020-06-23 | Cornell University | Compounds for MALT1 degredation |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| US10829482B2 (en) | 2016-12-27 | 2020-11-10 | Kao Corporation | Method for producing glyceric acid ester |
| EP3564226B1 (en) * | 2016-12-27 | 2021-06-02 | Kao Corporation | Method for producing glyceric acid ester |
| AU2017388710B2 (en) | 2016-12-27 | 2019-04-04 | Kao Corporation | Method for manufacturing 1,3-dioxane-5-one |
| WO2018141749A1 (en) | 2017-02-01 | 2018-08-09 | Medivir Ab | Therapeutic applications of malt1 inhibitors |
| WO2018159650A1 (ja) * | 2017-02-28 | 2018-09-07 | 東レ株式会社 | グアニジン誘導体及びその医薬用途 |
| EP3592731A4 (en) * | 2017-03-08 | 2020-10-07 | Cornell University | MALT1 INHIBITORS AND THEIR USES |
| WO2018226150A1 (en) * | 2017-06-05 | 2018-12-13 | Medivir Aktiebolag | Pyrazolopyrimidine as malt-1 inhibitors |
| CA3066591A1 (en) * | 2017-06-08 | 2018-12-13 | Mitsui Chemicals Agro, Inc. | Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients |
| JP7271540B2 (ja) * | 2017-11-17 | 2023-05-11 | へパジーン セラピューティクス （エイチケイ） リミテッド | Ａｓｋ１阻害剤としての尿素誘導体 |
| JP2021508720A (ja) | 2017-12-28 | 2021-03-11 | ザ ジェネラル ホスピタル コーポレイション | Ｃｂｍシグナロソーム複合体を標的にすることにより、制御性ｔ細胞に腫瘍微小環境の炎症を引き起こさせる方法 |
| EA202092962A1 (ru) * | 2018-06-18 | 2021-09-06 | Янссен Фармацевтика Нв | Производные пиразола в качестве ингибиторов malt1 |
| WO2019243964A1 (en) * | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Pyrazole derivatives as malt1 inhibitors |
| IL283368B2 (en) | 2018-11-28 | 2025-01-01 | Takeda Pharmaceuticals Co | Imidazo[2,1-b]pyridazin-7-yl urea compound and medicament containing the compound |
| CN109503473B (zh) * | 2019-01-07 | 2020-07-07 | 上海慧川生物医药科技有限公司 | 2-甲氧基-3-氨基-5-吡啶硼酸频哪醇酯及其中间体的合成方法 |
| EA202192320A1 (ru) | 2019-02-22 | 2021-11-16 | Янссен Фармацевтика Нв | Кристаллическая форма моногидрата 1-(1-оксо-1,2-дигидроизохинолин-5-ил)-5-(трифторметил)-n-[2-(трифторметил)пиридин-4-ил]-1h-пиразол-4-карбоксамида |
| WO2020208222A1 (en) | 2019-04-11 | 2020-10-15 | Janssen Pharmaceutica Nv | Pyridine rings containing derivatives as malt1 inhibitors |
| WO2021000855A1 (en) * | 2019-07-01 | 2021-01-07 | Qilu Regor Therapeutics Inc. | Malt1 inhibitors and uses thereof |
| CN111138437B (zh) * | 2019-12-04 | 2021-03-05 | 杭州华东医药集团新药研究院有限公司 | 取代的吡唑并[1,5-a]嘧啶氨基酸衍生物及其用途 |
| CA3161339A1 (en) * | 2019-12-27 | 2021-07-01 | Schrodinger, Inc. | Cyclic compounds and methods of using same |
| US20230192685A1 (en) * | 2020-05-27 | 2023-06-22 | Takeda Pharmaceutical Company Limited | Method for producing heterocyclic compound |
| US20230235077A1 (en) | 2020-06-24 | 2023-07-27 | The General Hospital Corporation | Materials and methods of treating cancer |
| TW202220992A (zh) | 2020-08-05 | 2022-06-01 | 匈牙利商羅特格登公司 | 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物 |
| CN116916924A (zh) * | 2020-10-16 | 2023-10-20 | 稀有生物科学股份有限公司 | Malt1调节剂及其用途 |
| EP4243812A1 (en) * | 2020-11-12 | 2023-09-20 | Monopteros Therapeutics, Inc. | Materials and methods of treating cancer |
| GB202018412D0 (en) | 2020-11-23 | 2021-01-06 | Exscientia Ltd | Malt-1 modulators ii |
| CN114805037B (zh) * | 2021-01-29 | 2025-08-19 | 河北圣泰材料股份有限公司 | 1,2-二甲氧基-1,1,2,2-四氟乙烷的合成方法 |
| US20250059196A1 (en) | 2021-12-30 | 2025-02-20 | Shanghai Hansoh Biomedical Co., Ltd. | Tricyclic derivative inhibitor, preparation method therefor, and application thereof |
| EP4466268A1 (en) * | 2022-01-18 | 2024-11-27 | Aurigene Oncology Limited | Substituted bicyclic heterocycles as malt-1 inhibitors |
| CN116535424B (zh) * | 2022-01-26 | 2025-04-11 | 武汉誉祥医药科技有限公司 | 作为malt1抑制剂的三并环化合物及其药物组合物和应用 |
| TW202340198A (zh) * | 2022-01-28 | 2023-10-16 | 大陸商上海齊魯製藥研究中心有限公司 | 靶向ｍａｌｔ１的蛋白降解化合物、包含其的醫藥組合物及其用途 |
| KR20240144146A (ko) | 2022-02-02 | 2024-10-02 | 오노 야꾸힝 고교 가부시키가이샤 | Malt1 저해약을 유효 성분으로서 포함하는 암 치료제 |
| JP2025506410A (ja) | 2022-02-03 | 2025-03-11 | シーフォーエックス・ディスカバリー・リミテッド | Ｍａｌｔ１阻害剤としてのヘテロ環誘導体 |
| WO2024182599A2 (en) * | 2023-03-01 | 2024-09-06 | Rarefied Biosciences, Inc. | Compositions and methods for treating malt1 associated diseases |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| US20020065296A1 (en) | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
| AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| WO2003091256A1 (en) * | 2002-04-23 | 2003-11-06 | Shionogi & Co., Ltd. | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME |
| JP4602076B2 (ja) | 2002-06-04 | 2010-12-22 | ネオジェネシス ファーマシューティカルズ インコーポレイテッド | 抗ウイルス剤としてのピラゾロ［１，５ａ］ピリミジン化合物 |
| WO2004022062A1 (en) * | 2002-09-04 | 2004-03-18 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US20060199846A1 (en) * | 2005-01-14 | 2006-09-07 | Mitchell Scott A | Certain substituted ureas as modulators of kinase activity |
| WO2008063671A2 (en) * | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
| US8309523B2 (en) | 2007-11-21 | 2012-11-13 | Vib Vzw | Inhibitors of MALT1 proteolytic activity and uses thereof |
| GB0821307D0 (en) | 2008-11-21 | 2008-12-31 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| CN102762208A (zh) * | 2009-12-04 | 2012-10-31 | 赛林药物股份有限公司 | 作为ck2抑制剂的吡唑嘧啶和相关杂环 |
| EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| EP2465928A1 (en) | 2010-12-16 | 2012-06-20 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Treatment of Th17-mediated diseases |
| WO2013028263A1 (en) * | 2011-08-24 | 2013-02-28 | Glaxosmithkline Llc | Pyrazolopyrimidine derivatives as pi3 kinase inhibitors |
| CN103570723B (zh) * | 2012-07-27 | 2016-07-13 | 广西梧州制药（集团）股份有限公司 | 吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途 |
| US9822118B2 (en) * | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| RS57117B1 (sr) | 2012-12-21 | 2018-06-29 | Plexxikon Inc | Jedinjenja i metode modulacije kinaze i povezane indikacije |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| CN103739550B (zh) * | 2014-01-02 | 2016-06-01 | 中国药科大学 | 2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用 |
-
2015
- 2015-05-27 SI SI201530825T patent/SI3149001T1/sl unknown
- 2015-05-27 PT PT15733899T patent/PT3149001T/pt unknown
- 2015-05-27 MY MYPI2016703450A patent/MY182487A/en unknown
- 2015-05-27 SG SG11201607895PA patent/SG11201607895PA/en unknown
- 2015-05-27 CR CR20160548A patent/CR20160548A/es unknown
- 2015-05-27 AU AU2015265478A patent/AU2015265478B2/en not_active Ceased
- 2015-05-27 CA CA2945077A patent/CA2945077A1/en not_active Abandoned
- 2015-05-27 EA EA201692105A patent/EA032050B1/ru not_active IP Right Cessation
- 2015-05-27 BR BR112016024545A patent/BR112016024545A2/pt active Search and Examination
- 2015-05-27 TW TW104117061A patent/TWI709561B/zh not_active IP Right Cessation
- 2015-05-27 RS RS20190905A patent/RS59039B1/sr unknown
- 2015-05-27 PL PL15733899T patent/PL3149001T3/pl unknown
- 2015-05-27 US US15/312,321 patent/US9815842B2/en active Active
- 2015-05-27 PE PE2016002391A patent/PE20170189A1/es unknown
- 2015-05-27 HU HUE15733899 patent/HUE044351T2/hu unknown
- 2015-05-27 KR KR1020167032664A patent/KR20170007311A/ko not_active Ceased
- 2015-05-27 JP JP2016569068A patent/JP6545197B2/ja not_active Expired - Fee Related
- 2015-05-27 TR TR2019/10730T patent/TR201910730T4/tr unknown
- 2015-05-27 CN CN201580020935.9A patent/CN106170489B/zh not_active Expired - Fee Related
- 2015-05-27 WO PCT/IB2015/053975 patent/WO2015181747A1/en not_active Ceased
- 2015-05-27 CU CU2016000181A patent/CU24393B1/es unknown
- 2015-05-27 DK DK15733899.7T patent/DK3149001T3/da active
- 2015-05-27 HR HRP20191261TT patent/HRP20191261T1/hr unknown
- 2015-05-27 ES ES15733899T patent/ES2738695T3/es active Active
- 2015-05-27 LT LTEP15733899.7T patent/LT3149001T/lt unknown
- 2015-05-27 AP AP2016009487A patent/AP2016009487A0/en unknown
- 2015-05-27 MX MX2016015544A patent/MX373846B/es active IP Right Grant
- 2015-05-27 EP EP15733899.7A patent/EP3149001B1/en active Active
- 2015-05-28 UY UY0001036143A patent/UY36143A/es not_active Application Discontinuation
- 2015-05-28 AR ARP150101686A patent/AR100645A1/es unknown
-
2016
- 2016-09-21 IL IL247949A patent/IL247949A0/en unknown
- 2016-09-22 PH PH12016501862A patent/PH12016501862B1/en unknown
- 2016-11-18 CL CL2016002942A patent/CL2016002942A1/es unknown
- 2016-11-28 SV SV2016005328A patent/SV2016005328A/es unknown
- 2016-11-28 GT GT201600249A patent/GT201600249A/es unknown
-
2017
- 2017-10-11 US US15/729,979 patent/US10442808B2/en not_active Expired - Fee Related
-
2019
- 2019-07-24 CY CY20191100786T patent/CY1121946T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170189A1 (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
| PE20211411A1 (es) | Compuestos de anillo fusionado | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| PE20210128A1 (es) | Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| PE20141974A1 (es) | Compuestos de heterociclilo | |
| PE20190395A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| PE20170695A1 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| NI201600152A (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
| PE20141597A1 (es) | Triazolopiridinas sustituidas | |
| PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
| PE20061442A1 (es) | Heterociclicos como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia | |
| MX388533B (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| PE20201185A1 (es) | Inhibidores de la oxacina monoacilglicerol lipasa (magl) | |
| PE20141582A1 (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
| PE20161443A1 (es) | Compuestos | |
| PE20141855A1 (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| PE20120534A1 (es) | PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| PE20191528A1 (es) | Nuevos derivados de triazolo[4,5-d]pirimidina | |
| PE20090984A1 (es) | Inhibidores de peptido desformilasa | |
| PE20090944A1 (es) | PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT | |
| PE20170186A1 (es) | Nuevos compuestos | |
| PE20121471A1 (es) | Derivados de sulfonamida heterociclicos utiles como inhibidores de mek |